Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for BioMed Research International, enter your email address in the box below.

BioMed Research International
Volume 2015, Article ID 917968, 14 pages
http://dx.doi.org/10.1155/2015/917968
Review Article

Somatostatin Receptor Based Imaging and Radionuclide Therapy

Caiyun Xu1,2,3,4 and Hong Zhang1,2,3,4

1Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China
2Zhejiang University Medical PET Center, Zhejiang University, Hangzhou, Zhejiang 310009, China
3Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, Zhejiang 310009, China
4Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, Zhejiang 310009, China

Received 19 September 2014; Revised 15 January 2015; Accepted 20 January 2015

Academic Editor: Enzo Terreno

Copyright © 2015 Caiyun Xu and Hong Zhang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Cuevas-Ramos and M. Fleseriu, “Somatostatin receptor ligands and resistance to treatment in pituitary adenomas,” Journal of Molecular Endocrinology, vol. 52, no. 3, pp. R223–R240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Sundin, U. Garske, and H. Örlefors, “Nuclear imaging of neuroendocrine tumours,” Best Practice and Research: Clinical Endocrinology & Metabolism, vol. 21, no. 1, pp. 69–85, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. W. J. Lamberts, E. P. Krenning, and J.-C. Reubi, “The role of somatostatin and its analogs in the diagnosis and treatment of tumors,” Endocrine Reviews, vol. 12, no. 4, pp. 450–482, 1991. View at Publisher · View at Google Scholar · View at Scopus
  4. L. C. Sun and D. H. Coy, “Somatostatin receptor-targeted anti-cancer therapy,” Current Drug Delivery, vol. 8, no. 1, pp. 2–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. C. Frühwald, M. S. O'Dorisio, T. Pietsch, and J. C. Reubi, “High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy,” Pediatric Research, vol. 45, no. 5, part 1, pp. 697–708, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Volante, R. Rosas, E. Allìa et al., “Somatostatin, cortistatin and their receptors in tumours,” Molecular and Cellular Endocrinology, vol. 286, no. 1-2, pp. 219–229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Theodoropoulou and G. K. Stalla, “Somatostatin receptors: from signaling to clinical practice,” Frontiers in Neuroendocrinology, vol. 34, no. 3, pp. 228–252, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Virgolini, T. Traub, M. Leimer et al., “New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy,” Quarterly Journal of Nuclear Medicine, vol. 44, no. 1, pp. 50–58, 2000. View at Google Scholar · View at Scopus
  9. M. Sorschag, P. Malle, and H.-J. Gallowitsch, “Nuclear medicine in NET,” Wiener Medizinische Wochenschrift, vol. 162, no. 19-20, pp. 416–422, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Shah, I. Kulakiene, A.-M. Quigley et al., “The role of 99mTc-depreotide in the management of neuroendocrine tumours,” Nuclear Medicine Communications, vol. 29, no. 5, pp. 436–440, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Virgolini, I. Szilvasi, A. Kurtaran et al., “Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients,” Journal of Nuclear Medicine, vol. 39, no. 11, pp. 1928–1936, 1998. View at Google Scholar · View at Scopus
  12. M. Gabriel, C. Decristoforo, D. Kendler et al., “68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 508–518, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. E. C. Etchebehere, A. de Oliveira Santos, B. Gumz et al., “68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial,” Journal of Nuclear Medicine, vol. 55, no. 10, pp. 1598–1604, 2014. View at Publisher · View at Google Scholar
  14. P. Sharma, S. Arora, A. Mukherjee et al., “Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified?” Clinical Nuclear Medicine, vol. 39, no. 1, pp. 37–43, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. Kwekkeboom, W. W. de Herder, C. H. J. van Eijck et al., “Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors,” Seminars in Nuclear Medicine, vol. 40, no. 2, pp. 78–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Muros, M. Varsavsky, P. Iglesias Rozas et al., “Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues,” Clinical and Translational Oncology, vol. 11, no. 1, pp. 48–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Khan, E. P. Krenning, M. Van Essen, B. L. Kam, J. J. Teunissen, and D. J. Kwekkeboom, “Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate,” Journal of Nuclear Medicine, vol. 52, no. 9, pp. 1361–1368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Buscail, N. Saint-Laurent, E. Chastre et al., “Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer,” Cancer Research, vol. 56, no. 8, pp. 1823–1827, 1996. View at Google Scholar · View at Scopus
  19. K. R. Zinn, D. J. Buchsbaum, T. R. Chaudhuri, J. M. Mountz, W. E. Grizzle, and B. E. Rogers, “Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re,” Journal of Nuclear Medicine, vol. 41, no. 5, pp. 887–895, 2000. View at Google Scholar · View at Scopus
  20. S. P. Singh, L. Han, R. Murali et al., “SSTR2-based reporters for assessing gene transfer into non-small cell lung cancer: evaluation using an intrathoracic mouse model,” Human Gene Therapy, vol. 22, no. 1, pp. 55–64, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Yuan, J. Wang, J. Deng et al., “Combination therapy in A549 cells,” Nuclear Medicine and Biology, vol. 37, no. 3, pp. 317–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Zhao, W. Yang, Z. Wang, G. Li, W. Qin, and J. Wang, “Treatment of transplanted tumor of lung adenocarcinoma A549 transfected by human somatostatin receptor subtype 2 (hsstr2) gene with 188Re-RC-160,” Nuclear Medicine and Biology, vol. 37, no. 8, pp. 977–987, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Zhang, M. A. Moroz, I. Serganova et al., “Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC,” Journal of Nuclear Medicine, vol. 52, no. 1, pp. 123–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. B. E. Rogers, S. F. McLean, R. L. Kirkman et al., “In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector,” Clinical Cancer Research, vol. 5, no. 2, pp. 383–393, 1999. View at Google Scholar · View at Scopus
  25. B. E. Rogers, J. J. Parry, R. Andrews, P. Cordopatis, B. A. Nock, and T. Maina, “MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and 94mTc-demotate 1,” Journal of Nuclear Medicine, vol. 46, no. 11, pp. 1889–1897, 2005. View at Google Scholar · View at Scopus
  26. K. Meyer, J.-C. Irminger, L. G. Moss et al., “Sorting human β-cells consequent to targeted expression of green fluorescent protein,” Diabetes, vol. 47, no. 12, pp. 1974–1977, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Bhaumik, X. Z. Lewis, and S. S. Gambhir, “Optical imaging of Renilla luciferase, synthetic Renilla luciferase, and firefly luciferase reporter gene expression in living mice,” Journal of Biomedical Optics, vol. 9, no. 3, pp. 578–586, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Okuwaki, M. Kida, T. Mikami et al., “Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes,” Cancer, vol. 119, no. 23, pp. 4094–4102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Sundin, “Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours,” Best Practice and Research: Clinical Gastroenterology, vol. 26, no. 6, pp. 803–818, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Cotugno, M. Aurilio, P. Annunziata et al., “Noninvasive repetitive imaging of somatostatin receptor 2 gene transfer with positron emission tomography,” Human Gene Therapy, vol. 22, no. 2, pp. 189–196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Cescato, S. Schulz, B. Waser et al., “Internalization of sst2, sst3, and sst5 receptors: effects of Somatostatin agonists and antagonists,” Journal of Nuclear Medicine, vol. 47, no. 3, pp. 502–511, 2006. View at Google Scholar · View at Scopus
  32. J. C. Reubi, B. Waser, R. Cescato, B. Gloor, C. Stettler, and E. Christ, “Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2343–2350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Fottner, E. Mettler, M. Goetz et al., “In vivo molecular imaging of somatostatin receptors in pancreatic islet cells and neuroendocrine tumors by miniaturized confocal laser-scanning fluorescence microscopy,” Endocrinology, vol. 151, no. 5, pp. 2179–2188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. D. J. Buchsbaum, T. R. Chaudhuri, and K. R. Zinn, “Radiotargeted gene therapy,” Journal of Nuclear Medicine, vol. 46, supplement 1, pp. 179s–186s, 2005. View at Google Scholar · View at Scopus
  35. I. Velikyan, A. Sundin, J. Sörensen et al., “Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification,” Journal of Nuclear Medicine, vol. 55, no. 2, pp. 204–210, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Kratochwil, F. L. Giesel, F. Bruchertseifer et al., “213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 11, pp. 2106–2119, 2014. View at Publisher · View at Google Scholar
  37. K. K. Wong, R. T. Waterfield, M. C. Marzola et al., “Contemporary nuclear medicine imaging of neuroendocrine tumours,” Clinical Radiology, vol. 67, no. 11, pp. 1035–1050, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. D. J. Kwekkeboom, B. L. Kam, M. van Essen et al., “Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors,” Endocrine-Related Cancer, vol. 17, no. 1, pp. R53–R73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Shan, “18F-Fluoroethyl triazole-βAG-[(d)-Phe1-c(Cys2-Tyr3-(d)-Trp4-Lys5-Thr6-Cys7)Thr8],” in Molecular Imaging and Contrast Agent Database (MICAD), National Center for Biotechnology Information, Bethesda, Md, USA, 2004. View at Google Scholar
  40. E. Bombardieri, M. Maccauro, E. De Deckere, G. Savelli, and A. Chiti, “Nuclear medicine imaging of neuroendocrine tumours,” Annals of Oncology, vol. 12, supplement 2, pp. S51–S61, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Ur, J. Bomanji, S. J. Mather et al., “Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide,” Clinical Endocrinology, vol. 38, no. 5, pp. 501–506, 1993. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Srirajaskanthan, I. Kayani, A. M. Quigley, J. Soh, M. E. Caplin, and J. Bomanji, “The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy,” Journal of Nuclear Medicine, vol. 51, no. 6, pp. 875–882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Hildebrandt, K. Scheidhauer, C. Luyken et al., “High sensitivity of the in vivo detection of somatostatin receptors by111Indium (DTPA-octreotide)-scintigraphy in meningioma patients,” Acta Neurochirurgica, vol. 126, no. 2-4, pp. 63–71, 1994. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Lebtahi, J. le Cloirec, C. Houzard et al., “Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy,” Journal of Nuclear Medicine, vol. 43, no. 7, pp. 889–895, 2002. View at Google Scholar · View at Scopus
  45. G. G. Bural, F. Lieberman, and J. M. Mountz, “Use of 111in-pentetreotide scan in a subject with treatment refractory atypical meningioma,” Clinical Nuclear Medicine, vol. 39, no. 4, pp. 342–345, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Bombardieri, V. Ambrosini, C. Aktolun et al., “111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 7, pp. 1441–1448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Pavel, E. Baudin, A. Couvelard et al., “ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary,” Neuroendocrinology, vol. 95, no. 2, pp. 157–176, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. U.-F. Pape, A. Perren, B. Niederle et al., “ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas,” Neuroendocrinology, vol. 95, no. 2, pp. 135–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. E. M. Blanchet, V. Martucci, and K. Pacak, “Pheochromocytoma and paraganglioma: current functional and future molecular imaging,” Frontiers in Oncology, vol. 1, article 58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. W. Xia, X. Zhang, F. Yu et al., “Experimental study of 99mTc-depreotide preparation and its affinity with A549 cell,” Frontiers in Bioscience, vol. 16, no. 7, pp. 2527–2539, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Axelsson, G. Herlin, M. Bth, P. Aspelin, and K. G. Kölbeck, “Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer,” Acta Radiologica, vol. 49, no. 3, pp. 295–302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Rodrigues, S. Li, M. Gabriel, D. Heute, M. Greifeneder, and I. Virgolini, “99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 3997–4000, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. B. van den Bossche, S. van Belle, F. de Winter, A. Signore, and C. Van De Wiele, “Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy,” Journal of Nuclear Medicine, vol. 47, no. 1, pp. 6–13, 2006. View at Google Scholar · View at Scopus
  54. A. Asnacios, F. Courbon, P. Rochaix et al., “Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 963–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Belhocine, J. Foidart, P. Rigo et al., “Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67,” Nuclear Medicine Communications, vol. 23, no. 8, pp. 727–734, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Kayani, J. B. Bomanji, A. Groves et al., “Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG,” Cancer, vol. 112, no. 11, pp. 2447–2455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Wild, H. R. Mäcke, B. Waser et al., “68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 6, p. 724, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Sharma, S. Arora, V. S. Dhull et al., “Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors,” Abdominal Imaging, vol. 40, no. 2, pp. 299–309, 2015. View at Publisher · View at Google Scholar
  59. C. B. Johnbeck, U. Knigge, and A. Kjær, “PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature,” Future Oncology, vol. 10, no. 14, pp. 2259–2277, 2014. View at Publisher · View at Google Scholar
  60. T. D. Poeppel, I. Binse, S. Petersenn et al., “68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors,” The Journal of Nuclear Medicine, vol. 52, no. 12, pp. 1864–1870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Wild, J. B. Bomanji, P. Benkert et al., “Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 54, no. 3, pp. 364–372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Bombardieri, M. Maccauro, M. R. Castellani et al., “Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?” Minerva Endocrinologica, vol. 26, no. 4, pp. 197–213, 2001. View at Google Scholar · View at Scopus
  63. A. Nikolaou, D. Thomas, C. Kampanellou et al., “The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center,” Journal of Endocrinological Investigation, vol. 33, no. 11, pp. 794–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Junik, P. Drobik, B. Małkowski, and K. Kobus-Błachnio, “The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET),” Advances in Medical Sciences, vol. 51, pp. 66–68, 2006. View at Google Scholar · View at Scopus
  65. G. A. Kaltsas, D. Papadogias, P. Makras, and A. B. Grossman, “Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 683–699, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Kaltsas, J. J. Mukherjee, P. N. Plowman, and A. B. Grossman, “The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours,” Clinical Endocrinology, vol. 55, no. 5, pp. 575–587, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Vogel, A. S. Atanacio, T. Prodanov et al., “External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma,” Frontiers in Oncology, vol. 4, article 166, 2014. View at Publisher · View at Google Scholar
  68. A. Mohamed, M. P. Blanchard, M. Albertelli et al., “Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures,” Endocrine-Related Cancer, vol. 21, no. 5, pp. 691–704, 2014. View at Publisher · View at Google Scholar
  69. M. Fani, H. R. Maecke, and S. M. Okarvi, “Radiolabeled peptides: valuable tools for the detection and treatment of cancer,” Theranostics, vol. 2, no. 5, pp. 481–501, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. E. P. Krenning, M. de Jong, P. P. M. Kooij et al., “Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy,” Annals of Oncology, vol. 10, supplement 2, pp. S23–S29, 1999. View at Google Scholar · View at Scopus
  71. L. B. Anthony, E. A. Woltering, G. D. Espenan, M. D. Cronin, T. J. Maloney, and K. E. McCarthy, “Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies,” Seminars in Nuclear Medicine, vol. 32, no. 2, pp. 123–132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. E. S. Delpassand, J. Sims-Mourtada, H. Saso et al., “Safety and efficacy of radionuclide therapy with high-activity in-111 pentetreotide in patients with progressive neuroendocrine tumors,” Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 3, pp. 292–300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Capello, E. P. Krenning, W. A. P. Breeman, B. F. Bernard, and M. de Jong, “Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide,” Journal of Nuclear Medicine, vol. 44, no. 1, pp. 98–104, 2003. View at Google Scholar · View at Scopus
  74. M. V. Davì, L. Bodei, M. Ferdeghini et al., “Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0,Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0,Tyr3]-octreotate) in ectopic Cushing syndrome from a metastatic gastrinoma: a promising proposal,” Endocrine Practice, vol. 14, no. 2, pp. 213–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. D. J. Kwekkeboom, W. H. Bakker, P. P. Kooij et al., “[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients,” European Journal of Nuclear Medicine, vol. 28, no. 9, pp. 1319–1325, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Ginj, K. Hinni, S. Tschumi, S. Schulz, and H. R. Maecke, “Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters,” Journal of Nuclear Medicine, vol. 46, no. 12, pp. 2097–2103, 2005. View at Google Scholar · View at Scopus
  77. S. Vinjamuri, T. M. Gilbert, M. Banks et al., “Peptide receptor radionuclide therapy with 90 Y-DOTATATE/90 Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity,” British Journal of Cancer, vol. 108, no. 7, pp. 1440–1448, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. L. Bodei, M. Cremonesi, C. M. Grana et al., “Yttrium-labelled peptides for therapy of NET,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, supplement 1, pp. S93–S102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. F. Forrer, C. Waldherr, H. R. Maecke, and J. Mueller-Brand, “Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors,” Anticancer Research, vol. 26, no. 1, pp. 703–707, 2006. View at Google Scholar · View at Scopus
  80. C. Waldherr, M. Pless, H. R. Maecke, A. Haldemann, and J. Mueller-Brand, “The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study,” Annals of Oncology, vol. 12, no. 7, pp. 941–945, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. D. J. Kwekkeboom, W. W. de Herder, B. L. Kam et al., “Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2124–2130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Sansovini, S. Severi, A. Ambrosetti et al., “Treatment with the radiolabelled somatostatin analog 177Lu-DOTATATE for advanced pancreatic neuroendocrine tumors,” Neuroendocrinology, vol. 97, no. 4, pp. 347–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. E. Seregni, M. Maccauro, C. Chiesa et al., “Treatment with tandem [90Y]DOTA-TATE and [177Lu] DOTA-TATE of neuroendocrine tumours refractory to conventional therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 2, pp. 223–230, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Imhof, P. Brunner, N. Marincek et al., “Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers,” Journal of Clinical Oncology, vol. 29, no. 17, pp. 2416–2423, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Nisa, G. Savelli, and R. Giubbini, “Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review,” Annals of Nuclear Medicine, vol. 25, no. 2, pp. 75–85, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. M. de Jong, W. A. P. Breeman, R. Valkema, B. F. Bernard, and E. P. Krenning, “Combination radionuclide therapy using 177Lu and 90Y-labeled somatostatin analogs,” Journal of Nuclear Medicine, vol. 46, no. 1, supplement, pp. 13S–17S, 2005. View at Google Scholar · View at Scopus
  87. A. Romer, D. Seiler, N. Marincek et al., “Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 2, pp. 214–222, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. J. C. Reubi, J.-C. Schär, B. Waser et al., “Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use,” European Journal of Nuclear Medicine, vol. 27, no. 3, pp. 273–282, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Forrer, H. Uusijärvi, D. Storch, H. R. Maecke, and J. Mueller-Brand, “Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC,” Journal of Nuclear Medicine, vol. 46, no. 8, pp. 1310–1316, 2005. View at Google Scholar · View at Scopus
  90. S. M. Bison, M. W. Konijnenberg, M. Melis et al., “Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments,” Clinical and Translational Imaging, vol. 2, no. 1, pp. 55–66, 2014. View at Publisher · View at Google Scholar
  91. F. Graf, J. Fahrer, S. Maus et al., “DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy,” PLoS ONE, vol. 9, no. 2, Article ID e88239, 2014. View at Publisher · View at Google Scholar
  92. S. T. Palayoor, J. L. Humm, R. W. Atcher, J. J. Hines, and R. M. Macklis, “G2M arrest and apoptosis in murine T lymphoma cells following exposure to 212Bi alpha particle irradiation,” Nuclear Medicine and Biology, vol. 20, no. 6, pp. 795–805, 1993. View at Publisher · View at Google Scholar · View at Scopus
  93. T. K. Nayak, J. P. Norenberg, T. L. Anderson, E. R. Prossnitz, M. G. Stabin, and R. W. Atcher, “Somatostatin-receptor-targeted α-emitting 213Bi is therapeutically more effective than β—emitting 177Lu in human pancreatic adenocarcinoma cells,” Nuclear Medicine and Biology, vol. 34, no. 2, pp. 185–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Miederer, G. Henriksen, A. Alke et al., “Preclinical evaluation of the α-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors,” Clinical Cancer Research, vol. 14, no. 11, pp. 3555–3561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. J. P. Norenberg, B. J. Krenning, I. R. H. M. Konings et al., “213Bi-[DOTA0,Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model,” Clinical Cancer Research, vol. 12, no. 3, part 1, pp. 897–903, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. D. T. Goodhead, “Mechanisms for the biological effectiveness of high-LET radiations,” Journal of Radiation Research, vol. 40, supplement, pp. 1–13, 1999. View at Google Scholar · View at Scopus
  97. K. Matthews, P. E. Noker, B. Tian et al., “Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer,” Clinical Cancer Research, vol. 15, no. 12, pp. 4131–4137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. S. M. Verwijnen, P. A. E. S. Smith, R. C. Hoeben et al., “Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene,” Cancer Biotherapy and Radiopharmaceuticals, vol. 19, no. 1, pp. 111–120, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. K. H. Kim, I. Dmitriev, J. P. O'Malley et al., “A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer,” Clinical Cancer Research, vol. 18, no. 12, pp. 3440–3451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Higashi, S. Hazama, A. Araki et al., “A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model,” International Journal of Oncology, vol. 45, no. 4, pp. 1412–1420, 2014. View at Publisher · View at Google Scholar
  101. K. R. Zinn, T. R. Chaudhuri, V. N. Krasnykh et al., “Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice,” Radiology, vol. 223, no. 2, pp. 417–425, 2002. View at Publisher · View at Google Scholar · View at Scopus
  102. M. ter Horst, S. M. Verwijnen, E. Brouwer et al., “Locoregional delivery of adenoviral vectors,” Journal of Nuclear Medicine, vol. 47, no. 9, pp. 1483–1489, 2006. View at Google Scholar · View at Scopus
  103. V. Akerstrom, C. Chen, M. S. Lan, and M. B. Breslin, “Adenoviral insulinoma-associated protein 1 promoter-driven suicide gene therapy with enhanced selectivity for treatment of neuroendocrine cancers,” Ochsner Journal, vol. 13, no. 1, pp. 91–99, 2013. View at Google Scholar · View at Scopus
  104. C. Capasso, M. Garofalo, M. Hirvinen, and V. Cerullo, “The evolution of adenoviral vectors through genetic and chemical surface modifications,” Viruses, vol. 6, no. 2, pp. 832–855, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. M. G. Castro, M. Colfi, T. J. Wilson et al., “Adenoviral vector-mediated gene therapy for gliomas: coming of age,” Expert Opinion on Biological Therapy, vol. 14, no. 9, pp. 1241–1257, 2014. View at Publisher · View at Google Scholar
  106. E. Zinn and L. H. Venberghe, “Adeno-associated virus: fit to serve,” Current Opinion in Virology, vol. 8, pp. 90–97, 2014. View at Publisher · View at Google Scholar
  107. D. Ibraheem, A. Elaissari, and H. Fessi, “Gene therapy and DNA delivery systems,” International Journal of Pharmaceutics, vol. 459, no. 1-2, pp. 70–83, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. L. S. Young, P. F. Searle, D. Onion, and V. Mautner, “Viral gene therapy strategies: from basic science to clinical application,” Journal of Pathology, vol. 208, no. 2, pp. 299–318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. J. A. McCart, N. Mehta, D. Scollard et al., “Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide,” Molecular Therapy, vol. 10, no. 3, pp. 553–561, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. D. E. Hruby, “Vaccinia virus vectors: new strategies for producing recombinant vaccines,” Clinical Microbiology Reviews, vol. 3, no. 2, pp. 153–170, 1990. View at Google Scholar · View at Scopus
  111. N. Wang, H. Zhang, B.-Q. Zhang et al., “Adenovirus-mediated efficient gene transfer into cultured three-dimensional organoids,” PLoS ONE, vol. 9, no. 4, Article ID e93608, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. S. Nair, D. T. Curiel, V. Rajaratnam, C. Thota, and A. Al-Hendy, “Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas,” Human Reproduction, vol. 28, no. 9, pp. 2398–2406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. F. McCormick, “Cancer gene therapy: fringe or cutting edge?” Nature Reviews Cancer, vol. 1, no. 2, pp. 130–141, 2001. View at Publisher · View at Google Scholar · View at Scopus
  114. V. Kundra, F. Mannting, A. G. Jones, and A. I. Kassis, “Noninvasive monitoring of somatostatin receptor type 2 chimeric gene transfer,” Journal of Nuclear Medicine, vol. 43, no. 3, pp. 406–412, 2002. View at Google Scholar · View at Scopus
  115. A. Hemminki, N. Belousova, K. R. Zinn et al., “An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression,” Molecular Therapy, vol. 4, no. 3, pp. 223–231, 2001. View at Publisher · View at Google Scholar · View at Scopus
  116. M. van Essen, E. P. Krenning, B. L. R. Kam, M. de Jong, R. Valkema, and D. J. Kwekkeboom, “Peptide-receptor radionuclide therapy for endocrine tumors,” Nature Reviews Endocrinology, vol. 5, no. 7, pp. 382–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. O. Akinlolu, K. Ottolino-Perry, J. A. McCart, and R. M. Reilly, “Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor,” Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 3, pp. 325–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Takahashi, T. Sato, T. Sagawa et al., “E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor,” Molecular Therapy, vol. 5, no. 5, pp. 627–634, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. B. E. Rogers, K. R. Zinn, C.-Y. Lin, T. R. Chaudhuri, and D. J. Buchsbaum, “Targeted radiotherapy with [90Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector,” Cancer, vol. 94, supplement 4, pp. 1298–1305, 2002. View at Publisher · View at Google Scholar · View at Scopus
  120. L.-P. Chai, Z.-F. Wang, W.-Y. Liang et al., “In vitro and in vivo effect of 5-FC combined gene therapy with TNF-alpha and CD suicide gene on human laryngeal carcinoma cell line Hep-2,” PLoS ONE, vol. 8, no. 4, Article ID e61136, 2013. View at Publisher · View at Google Scholar · View at Scopus